PFE — Pfizer, Inc. Common Stock
Session close: $29.39. Regular-session share volume: 29,174,315. Change from previous close: -1.64%.
Key developments
DZ Bank downgraded Pfizer to Hold from Buy while setting a price target, reflecting a more cautious analyst view of the company's market position and outlook. Separately, Guggenheim raised its price target on the shares, an updated valuation call.
Company news DZ Bank Downgrades Pfizer to Hold From Buy · Company news Guggenheim Adjusts Pfizer Price Target to $33
Coverage also framed Pfizer as attractive for income investors, citing a well-covered dividend and modest valuation, with the stock having outperformed the broader market alongside the healthcare sector. A market report on hemophilia B gene therapy listed Pfizer among companies advancing AAV-based treatments, tying it to a growing therapy category.
Company news Pfizer (PFE) Stock Looks Attractive for Income Investors · Company news Global Hemophilia B Gene Therapy Market Report 2026 | Capitalize on 29.8% CAGR as Pfizer, CSL Behring, Bayer, and REGENXBIO Accelerate AAV Innovation
News sources
Company news Global Hemophilia B Gene Therapy Market Report 2026 | Capitalize on 29.8% CAGR as Pfizer, CSL Behring, Bayer, and REGENXBIO Accelerate AAV Innovation · Company news DZ Bank Downgrades Pfizer to Hold From Buy · Company news Pfizer (PFE) Stock Looks Attractive for Income Investors · Company news Guggenheim Adjusts Pfizer Price Target to $33 · Company news Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 · Company news Pfizer Canada Celebrates 30-Year Partnership with Canadian Paralympic Committee · Company news This Former Mylan/Pfizer Combo Backed Into Its Buy Zone — What You Should Know